Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
80.15 EUR | -2.27% |
|
-3.24% | +18.37% |
Jul. 16 | Truist Raises Price Target on Edwards Lifesciences to $110 From $105, Maintains Buy Rating | MT |
Jul. 15 | Sector Update: Health Care Stocks Edge Lower Late Afternoon | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analyst opinion has improved significantly over the past four months.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 33.21 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+18.37% | 53.93B | - | ||
+4.64% | 208B | B | ||
+8.99% | 182B | B- | ||
+29.83% | 155B | B- | ||
+35.17% | 115B | A- | ||
+2.55% | 66.52B | A- | ||
-6.47% | 46.26B | B+ | ||
-2.14% | 38.22B | A | ||
+6.88% | 36.6B | - | ||
+20.22% | 30.16B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- EW Stock
- EWL Stock
- Ratings Edwards Lifesciences Corporation